ALX Oncology Holdings Inc (ALXO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.84-8.00%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
ALX Oncology is advancing key cancer drug programs with important readouts. It beat Q1 2026 earnings forecasts. The company is working on new therapies for cancer patients. These steps could lead to future growth.
ALX Oncology is loss-making and has missed earnings several times. It has no revenue yet and negative earnings expected through 2027. The company faces high risk and volatile management. These issues could delay or prevent success.
The market values ALX with optionality but expects continued losses. Our fair value is about $0.89 per share. We see risk in the lack of revenue and ongoing losses.
Breaks if: default on debt or liquidity runs out before FY27
Breaks if: miss key clinical readouts by mid-2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is mixed, with management focusing on advancing oncology therapies while facing high operational risks.
The market appears to be pricing in a fragile valuation, as ALXO is seen as expensive relative to peers despite its weak fundamentals. The expectations seem to be based on the potential for optionality in its clinical developments.
Fundamentals are likely to remain neutral in the near term, with management making progress on clinical milestones while maintaining sufficient cash to fund operations. However, the company is still loss-making, which adds to the uncertainty.
The thesis hinges on several factors, including management's ability to meet clinical milestones, the performance of sector bellwethers, and broader economic conditions impacting the healthcare sector. Any negative guidance or economic downturn could significantly affect sentiment.
The most important moves since the prior daily snapshot.
Company momentum fell by 33.4 points (from 35.6 to 2.2).
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens or stays flat through FY27
Breaks if: no revenue generated by end of FY27
In the next 1 to 3 years, ALXO's prospects will depend on clinical progress and external market conditions. Not investment advice.